Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. reports clinical and corporate developments for its T cell receptor-engineered T cell therapy pipeline. The company’s cancer programs include TSC-101 in the ALLOHA heme trial for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, and CD45-targeted candidates TSC-102-A01 and TSC-102-A03 with cleared IND applications.
Recurring TCRX updates cover clinical data presentations, trial enrollment and manufacturing-process updates, FDA interactions, financial results, healthcare conference participation, and portfolio priorities. The company also describes early work in in vivo engineering for solid tumors and target discovery in T cell-mediated autoimmune disorders.
TScan Therapeutics announced the pricing of its initial public offering (IPO) on July 15, 2021, of 6,666,667 shares at a price of $15.00 each, raising $100 million before expenses. The offering will close around July 20, 2021, pending customary conditions. An additional 1,000,000 shares may be purchased by underwriters within 30 days. The stock is set to trade on Nasdaq under the symbol TCRX starting July 16, 2021. The company specializes in T-cell receptor-engineered therapies for cancer treatment.